Follow us on:

Linkedin Facebook

Poolbeg Pharma to announce results for the period ended 31 December 2021 on 3 March 2022

Poolbeg Pharma

Poolbeg Pharma plc (LON:POLB) a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, will announce its results for the period ended 31 December 2021 on Thursday 3 March 2022.

The Company will be hosting an online presentation for investors on the same day, at 6:00pm GMT on the Investor Meet Company platform.

The presentation is open to all existing and potential shareholders. Investors can register to attend here: www.investormeetcompany.com/poolbeg-pharma-plc/register-investor 

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Poolbeg Pharma

Poolbeg Pharma CEO participating in key conferences in March and April 2025

Poolbeg Pharma's CEO, Jeremy Skillington, will present at major industry conferences in March and April 2025, showcasing innovative therapies and advancements.
Poolbeg Pharma

Poolbeg Pharma granted patent in Korea for POLB 001

Poolbeg Pharma (LON:POLB) secures a crucial patent for POLB 001 in South Korea, enhancing its portfolio for treating severe influenza and other conditions.
Poolbeg Trading

Poolbeg Pharma granted extension to PUSU Deadline

HOOKIPA Pharma and Poolbeg Pharma enter talks for a potential acquisition aimed at developing next-generation immunotherapies for critical medical needs.
Poolbeg Pharma

Poolbeg Pharma update on potential combination with HOOKIPA

Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations.
Poolbeg Pharma

Poolbeg Pharma y HOOKIPA Pharma actualizan su recaudación de fondos con el apoyo de Gilead Sciences

Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos.
Poolbeg Pharma

Poolbeg Pharma and HOOKIPA Pharma fundraise update with Gilead Sciences’ support

Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks.

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.